ClinicalTrials.gg

Program

adimanebart

Also written as “ARGX-119”, “Adimanebart IV” and “ARGX-119 IV”.

Its studies are mostly in Muscular Atrophy, Spinal · Amyotrophic Lateral Sclerosis, led by argenx.

Furthest: phase 3, since Jul 30, 20266 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
argenx64 open or runningphase 3since Jul 30, 2026Dec 20, 2022Dec 2026phase 1 · NCT07673601

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 20, 2022First study: phase 1 study in Healthy VolunteersFirst studyNCT05670704 · 112 enrolled · Netherlands
  2. May 21, 2024Phase 1 study in Myasthenic Syndromes, CongenitalNCT06436742 · 15 enrolled · United States, Canada, France and more
  3. May 29, 2024Phase 2 study in Amyotrophic Lateral SclerosisNCT06441682 · 60 enrolled · Belgium, Canada, Denmark and more
  4. Dec 15, 2025Phase 2 study in Muscular Atrophy, SpinalNCT07287982 · 60 planned · United States, Australia, Canada and more
  5. Jun 23, 2026Phase 1 study in Healthy Volunteers (HV)NCT07673601 · 52 planned · Canada
  6. Jul 30, 2026Phase 3 study in Myasthenic Syndromes, CongenitalPhase 3 reachedNCT07746089 · 105 planned

Ahead

  1. Dec 2026Primary completion: phase 1 study in Healthy Volunteers (HV)NCT07673601
  2. Aug 24, 2027Primary completion: phase 1 study in Myasthenic Syndromes, CongenitalNCT06436742
  3. May 28, 2029Primary completion: phase 2 study in Muscular Atrophy, SpinalNCT07287982
  4. Oct 2030Primary completion: phase 3 study in Myasthenic Syndromes, CongenitalNCT07746089

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07746089Myasthenic Syndromes, Congenital3Not yet recruitingOct 2030105
NCT07673601Healthy Volunteers (HV) · Canada1RecruitingDec 202652
NCT07287982Muscular Atrophy, Spinal · United States, Australia, Canada and more2RecruitingMay 28, 202960
NCT06441682Amyotrophic Lateral Sclerosis · Belgium, Canada, Denmark and more2TerminatedAug 12, 202660
NCT06436742Myasthenic Syndromes, Congenital · United States, Canada, France and more1Active, not recruitingAug 24, 202715
NCT05670704Healthy Volunteers · Netherlands1CompletedAug 8, 2024112

How it is read

Names in the registry

  • “ARGX-119”, 3 entries
  • “Adimanebart IV”, 2 entries
  • “ARGX-119 IV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.